Mannelijke vruchtbaarheid na een hoge dosis radioactief jodium voor de behandeling van gedifferentieerd schildklierkanker

All males (age ¡Ý 18y) diagnosed with DTC in the Netherlands from January 2008 that are at least ¡Ý2 years after their last treatment with a high cumulative dose of radioiodine (¡Ý 100 mCi/3.7 GBq) are eligible for inclusion.

A potential subject who meets any of the following criteria will be excluded from participation in this study:

- Use of drugs that interact with semen quality (i.e. testosterone suppletion, chemotherapy);

- Use of anabolic steroids;

- Fever (body temperature >38¡ãC) in the three months before semen analysis;

- Gonadal/testicular diseases or treatments that are associated with impairment of semen quality;

- Active disease state (widespread metastases, under active treatment for DTC or active treatment with systemic therapy/radiotherapy);

- Attained age older than 60 years;

- I-131 only administered combined with use of recombinant human TSH (rhTSH) and no thyroid hormone withdrawal therapy before I-131 administrations;

or

- Non-compliance of thyroid hormone substitution, resulting in several measurements of TSH >10 mU/l in the last year before evaluation.